Female Sex and Higher Drug Dose as Risk Factors for Late Cardiotoxic Effects of Doxorubicin Therapy for Childhood Cancer
Why the study?
Do female sex and higher doxorubicin dose increase the risk of late cardiotoxic effects in childhood cancer survivors?
Population
120 children and adults who had received cumulative doses of 244 to 550 mg/m2 of doxorubicin for the…
Comparison
Doxorubicin therapy vs Cohort of 296 normal subjects
Design
Cohort
Follow-up
mean 8.1 years
Authors
Discussion
Loading...
Member takes
Implication
May inform sex- and dose-based surveillance in survivors; leaves open need for prospective validation of interventions.
Structured PICO
Do female sex and higher doxorubicin dose increase the risk of late cardiotoxic effects in childhood cancer survivors?
P
Population
120 children and adults who had received cumulative doses of 244 to 550 mg/m2 of doxorubicin for the treatment of acute lymphoblastic leukemia or osteogenic sarcoma in childhood
I
Intervention
Doxorubicin therapy (cumulative doses 244 to 550 mg/m2)
C
Comparator
Cohort of 296 normal subjects
O
Outcome
Echocardiographic measurements of left ventricular function, contractility, end-diastolic posterior-wall thickness, end-diastolic dimension, mass, and afterloadsurrogate
Female sex, higher cumulative dose, and higher rate of administration of doxorubicin are independent risk factors for late echocardiographic cardiac abnormalities in childhood cancer survivors.
Cite This Study
Lipshultz et al. (1995) studied this question.